FDA Grants Pembrolizumab Priority Review for Advanced Gastric Cancer

May 24, 2017 – The FDA has granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of patients who have undergone at least 2 courses of chemotherapy for recurrent or advanced gastric or gastroesophageal junction adenocarcinoma. The agency is expected to announce a decision by September 22, 2017. “An estimated 100,000 people are living with gastric cancer in the United States, yet little progress … (leggi tutto)